COGNEX CORP annual report, FY2012

Cognex Corporation (NASDAQ: CGNX) — 2012 Form 10-K

Business context and reporting period. Machine-vision products and services provider serving manufacturing and logistics applications. Fiscal year ended December 31, 2012; the filing also reports fourth-quarter results. MVSD accounted for about 84% of annual revenue; SISD focuses on continuous-material surface inspection.

Financial performance and position

Dollar amounts below are in millions, except per-share data and percentages.

MetricFY 2012FY 2011
Revenue$324.3$321.9
Gross profit / gross margin$244.8 / 75.5%$244.0 / 75.8%
Operating income / margin$83.4 / 25.7%$85.4 / 26.5%
Net income / diluted EPS$68.1 / $1.56$69.9 / $1.63
Cash from operations$101.1$86.3
Capital expenditures$9.9$7.8
  • Fourth-quarter 2012 revenue was $82.2 million, operating income $20.5 million, and net income $16.2 million; diluted EPS was $0.37.
  • Annual product revenue declined 1% to $295.6 million, while service revenue rose 17% to $28.7 million. Product gross margin held at 78%; service gross margin improved to 51% from 46%.
  • Factory automation revenue increased 4% reported (7% excluding currency effects); surface inspection rose 5%; semiconductor and electronics capital-equipment revenue fell 24%.
  • At year-end, cash and investments totaled $388.5 million, working capital was $189.5 million, total assets were $627.6 million, and shareholders’ equity was $572.3 million. Cognex reported no long-term debt and no off-balance-sheet arrangements.
  • Operating cash flow increased to $101.1 million. Cash dividends paid were $66.2 million, including accelerated and special dividends.

Changes, outlook, risks, and unusual items

  • Revenue rose just 1% year over year as growth in factory automation and surface inspection was largely offset by the cyclical semiconductor/electronics decline. Operating income and net income decreased despite higher operating cash flow.
  • Management identified China and ID products as expected growth opportunities in 2013 and expected to continue significant R&D investment, targeting R&D spending of 10%–15% of revenue. The filing provides no specific consolidated revenue or earnings guidance.
  • Management cited slower consumer-electronics demand in China late in 2012 and limited visibility in the cyclical semiconductor/electronics market. Other key risks include global manufacturing spending, automotive exposure, international operations and currency movements, supplier concentration, product transitions, competition, and execution in logistics automation.
  • Dividend payments included $1.11 per share accelerated in Q4 2012: $0.11 ordinarily expected in early 2013 and a $1.00 special dividend intended to replace expected dividends for 2013–2014. Future dividends remain at the Board’s discretion.
  • The company recorded $0.88 million of foreign-currency losses; a hedge related to converting its Euro investment portfolio generated a $0.50 million loss. A 2013 tax-law change was expected to reduce Q1 2013 tax expense by approximately $0.56 million.
  • Patent litigation against MvTec and related parties remained ongoing on appeal after an adverse ITC determination; the company said an adverse outcome could materially affect financial position, liquidity, results, or indemnification obligations. No significant contingency accrual was reported.
  • Grant Thornton gave unqualified opinions on the financial statements and internal control over financial reporting. No impairment charges were recorded in 2012.

Important facts for investors to verify

  • Whether factory-automation and ID-product growth can offset continuing weakness or cyclicality in semiconductor/electronics customers.
  • Whether reported margin and earnings trends improve, particularly given lower product revenue and increased strategic headcount and investment.
  • Liquidity composition and investment risks, including the $3.7 million carrying value of the venture-capital partnership interest (estimated fair value $6.9 million) and potential impairment exposure.
  • Developments and potential financial exposure in the pending patent appeal and tax examinations or reserves.
  • Dividend policy and capital allocation after the unusually large 2012 accelerated and special payments; confirm that future distributions are not assured.